Ojjaara (momelotinib) — United Healthcare
secondary myelofibrosis [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)] with anemia
Initial criteria
- Patient is less than 19 years of age
Reauthorization criteria
- Continuation per age-based provision
Approval duration
12 months